Hisun Pharmaceutical’s prostate cancer treatment drug has been approved for market launch
May 26, 2026
Source: drugdu
25
Recently, Hisun Pharmaceutical announced that it has received a Drug Registration Certificate for apalutamide tablets (60mg) issued by the National Medical Products Administration (NMPA) for the treatment of adult patients with metastatic endocrine therapy-sensitive prostate cancer (mHSPC) and adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) with a high risk of metastasis.
According to the "Analysis of the Epidemiological Situation of Malignant Tumors in China in 2022" released by the National Cancer Center in 2024, the number of newly diagnosed prostate cancer cases reached 134,000, and the number of deaths reached 48,000, ranking sixth among male malignant tumors. As one of the most common malignant tumors in men, there is a strong market demand for apalutamide. According to IQVIA database statistics, global sales of apalutamide tablets are estimated at approximately US$5.202 billion in 2025, with domestic sales in China accounting for approximately US$85.7771 million.
https://mp.weixin.qq.com/s/m2Q8h0C5A-yyIwBwEyudCw
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Good news! Asartan potassium tablets have been approved May 26, 2026
- Huadong Medicine’s first precision-targeting EGFR exon 21 (L858R) innovative drug, mefanilinib maleate (Mindray®), was prescribed for the first time nationwide May 26, 2026
- Progen Pharmaceuticals’ metoprolol succinate extended-release tablets have received FDA approval in the United States for a new 25mg specification. May 26, 2026
- Japanese pharmaceutical giant ordered to pay 17 billion yen in damages. May 26, 2026
- Big news! Johnson & Johnson’s new autoimmune drug nicalimab approved in China May 26, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
